MCED blood tests detect what a tumor has already left behind. xTenure reads the biological trajectory that leads there — years earlier — from your medical history.
Latent disease discovery is not early detection. It is pre-early detection: identifying the trajectory of biological change before any tumor forms, before any marker spills into the bloodstream, before any symptom appears.
Every cancer that MCED tests eventually detect began years earlier as a silent biological drift — a trajectory of micro-changes in how your body processes, signals, and adapts. xTenure reads that trajectory. MCED reads its consequences.
Multi-cancer early detection tests — Galleri, OncoSeek, and others — are powerful tools. They detect protein markers, cell-free DNA fragments, and other biological signals that tumors shed into the bloodstream. But a tumor must already exist and be of sufficient size to shed detectable signal. Detection, however early, is detection of a disease already present.
Your complete medical history — labs, diagnoses, prescriptions, vitals, procedures, over years — contains a latent biological story. Subtle deviations in CA 19-9 trends, a sequence of GI visits, a new-onset metabolic shift: individually unremarkable. As a trajectory, they point to where your biology is going. xTenure reads that trajectory years before any tumor would be detectable.
Every cancer has a natural history — a progression from normal biology through latent trajectory to tumor formation to clinical presentation. xTenure operates at the earliest detectable stage of that journey.
Reading biological trajectories from longitudinal health records to identify where patient biology is heading — before any tumor exists to detect.
Blood-based tests detect signals shed by existing tumors. Powerful and important — but operating downstream of xTenure's detection window. xTenure identifies who needs MCED testing.
The majority of cancers are still diagnosed here. Stage III–IV diagnosis. Where survival outcomes are dramatically worse. Where the full burden of late-stage treatment falls.
A four-stage architecture that transforms longitudinal health records into disease trajectories, risk scores, and admissible clinical actions.
xTenure's AI reads your complete longitudinal medical record — labs, diagnoses, medications, procedures, vitals — not as isolated events but as a biological trajectory. It infers the latent biological history that your observed records are a partial, fragmented reflection of. This is where the disease signal lives — in the pattern of the whole, not any single finding.
From the latent history, xTenure projects forward: a disease-aware probability distribution over future biological states at a 3–5 year horizon. Not a single risk score — a structured distribution that specifies which disease branches are active, which are approaching transition thresholds, and how confident the model is in each trajectory. For cancer, it specifies which of nine cancer types the trajectory is consistent with.
The trajectory distribution feeds a three-gate architecture. Gate 1 asks: is the evidence strong enough to act? Gate 2 asks: what is the most economically justified action? Gate 3 asks: is the healthcare system able to absorb the recommended intervention load? Together, the gates produce an admissible action — the right intervention for the right patient at the right time, defensible to clinicians, payers, and regulators.
For patients whose trajectory reaches the pre-tumor threshold, xTenure recommends targeted MCED testing — directing blood-based cancer detection to exactly the individuals most likely to test positive. This makes MCED economically viable at population scale. For clinicians, xTenure provides the most informative next test, the most probable biological narrative, and the intervention with the highest expected clinical value.
Complete longitudinal record ingested. Bayesian compressed sensing constructs the history cloud — the posterior over all plausible biological histories.
Disease-aware probability distribution over 3–5 year biological futures. Nine cancer branches. Structured uncertainty.
Three-gate architecture. Decision sufficiency, economic justification, system feasibility. Admissible action produced.
Directed MCED testing. Clinical decision support. Insurance underwriting. DTC health risk reporting.
xTenure's platform is not a pattern-matching engine. It is grounded in Bayesian inference, stochastic dynamics, and information geometry — producing principled uncertainty quantification and theoretically defensible clinical recommendations.
xTenure's platform serves the full spectrum of healthcare decision-makers — from individual patients to population-scale health systems.
Population-level latent disease surveillance. Proactive identification of high-risk individuals years before expensive late-stage presentation. A direct path to reduced cancer mortality and lower long-term cost burden.
Longitudinal risk stratification for underwriting. Admissible-action architecture designed for insurance portfolio constraints. Actuarially sound, individually precise, and gate-validated for regulatory compatibility.
xTenure directs blood-based cancer detection to the individuals most likely to test positive — making MCED economically viable at national scale. A pre-screening funnel that multiplies the clinical and commercial impact of every MCED test ordered.
Partnering with leading consumer health platforms to give individuals access to their own biological trajectory — personalized cancer risk years in advance, with the most informative next step clearly identified.
Latent disease discovery across nine cancer types using the largest longitudinal US patient dataset deployed for this purpose. A platform for pre-diagnostic signal research, lead-time analysis, and cancer trajectory modeling.
A low-cost, EHR-based pre-screening layer that makes MCED economically viable in settings where blanket blood-based screening is not. Designed for interoperability with existing health information infrastructure worldwide.
Whether you represent a health system, insurer, MCED partner, research institution, or investment organization — we welcome a briefing on how xTenure can transform cancer detection outcomes for your population.
